ViiV Healthcare

http://www.viivhealthcareeffect.com

22.11.2017 – 01:37
Juluca® (Dolutegravir and Rilpivirine) Approved in US as First 2-drug Regimen, Once-daily, Single Pill - a Complete Regimen for the Maintenance Treatment of Virologically Suppressed HIV-1 Infection
London (ots/PRNewswire) - ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Juluca®, indicated as a complete regimen for the maintenance treatment ...
mehr
25.07.2017 – 15:07
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
London (ots/PRNewswire) - DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive interim results from DAWNING. This is a ...
mehr
16.08.2016 – 14:58
ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment
London (ots/PRNewswire) - ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy. (Logo: ...
mehr
18.07.2016 – 12:16
ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV
London, England and Durban, South Africa (ots/PRNewswire) - ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) ...
mehr
10.06.2016 – 15:18
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
London (ots/PRNewswire) - Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral ...
mehr
24.02.2016 – 18:16
ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir
London (ots/PRNewswire) - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the 41 week phase IIa ECLAIR study, which evaluated the safety, tolerability, dosing and satisfaction with the ...
mehr
23.02.2016 – 20:52
ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment
London (ots/PRNewswire) - 32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented ...
mehr
07.01.2016 – 14:34
ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection
London (ots/PRNewswire) - ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with Janssen Sciences Ireland UC (Janssen) for the phase III investigation and commercialisation of the long-acting, injectable formulations of ...
mehr
03.11.2015 – 14:28
ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy
London (ots/PRNewswire) - ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations ...
mehr

26.10.2015 – 15:31
ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally
London (ots/PRNewswire) - ViiV Healthcare today awarded its first round of small grants to support men who have sex with men (MSM) and transgender community-led interventions to reduce stigma and discrimination based on sexual orientation, gender identity/expression and/or HIV status. 23 non-governmental and ...
mehr
23.09.2015 – 11:31
New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression
London (ots/PRNewswire) - ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and tolerability of switching from an antiretroviral therapy (ART) to the once-daily, fixed-dose dolutegravir-based regimen, Triumeq(R) (abacavir/dolutegravir/lamivudine) in virologically suppressed adults ...
mehr
26.05.2015 – 15:03
ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV
London (ots/PRNewswire) - ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment ...
mehr
06.05.2015 – 10:55
ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy
London (ots/PRNewswire) - First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay(R)) and rilpivirine (Edurant(R)[1]) as maintenance ...
mehr
25.10.2013 – 14:26
ViiV Healthcare announces European regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
London (ots/PRNewswire) - ViiV Healthcare today announced the submission of a regulatory application in Europe for its investigational single-tablet regimen (STR) combining dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) for the treatment of people living with HIV. This Marketing Authorisation Application ...
mehr